Keywords: Cell Surface Receptor, Echistatin, Integrin, N Ethyl N [4 (4 Piperidinyl)butyryl]glycylaspartyl 3 Cyclohexylalaninamide, Synthetic Peptide, Unclassified Drug, Vitronectin Receptor, Vitronectin Receptor Antagonist, Angiogenesis, Article, Cell Adhesion, Cell Strain K 562, Crystal Structure, Endothelium Cell, Erythroleukemia Cell, Melanoma Cell, Metastasis, Molecular Model, Nuclear Magnetic Resonance Spectroscopy, Peptide Synthesis, X Ray Diffraction, Crystallography, X-Ray, Drug Design, Humans, Integrin Alphavbeta3, K562 Cells, Molecular Mimicry, Molecular Structure, Oligopeptides, Radioligand Assay, N Ethyl N [4 (4 Piperidinyl) Butyryl] Glycylaspartyl 3 Cyclohexylalaninamide, Cell Adhesion Drug Effects, Integrin Alphavbeta3 Antagonists, Inhibitors Biosynthesis Chemistry, Integrins Biosynthesis, Oligopeptides Chemical Synthesis Chemistry Pharmacology, Vitronectin Biosynthesis, Vitronectin Physiology,
Affiliations: *** IBB - CNR ***
Institute of Biostructures and Bioimaging, Department of Biological Sciences, University of Naples Federico II, via Mezzocannone 16, 80134 Naples, Italy
Department of Pharmaceutical and Toxicological Chemistry, University of Naples Federico II, via D. Montesano 49, 80131 Naples, Italy
References: Not available.
Novel And Selective Alpha (v) Beta3 Receptor Peptide Antagonist: Design, Synthesis, And Biological Behavior
Among RGD-dependent integrins, the alpha (v) beta3 receptor has recently received increasing attention as a therapeutic target because of its critical role in tumor-induced angiogenesis and metastasis formation. Here, we describe a new peptide antagonist of alpha (v) beta3 receptor, designed on the basis of the crystal structure of integrin alpha (v) beta3 in complex with c (RGDf [NMe] V) and the NMR structure of echistatin. Cell adhesion assays have demonstrated that the peptide is a potent and selective antagonist of the alpha (v) beta3 receptor
Novel And Selective Alpha (v) Beta3 Receptor Peptide Antagonist: Design, Synthesis, And Biological Behavior
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(433 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote